A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

  • Jeremy M. Shefner
  • , Jinsy A. Andrews
  • , Angela Genge
  • , Carlayne Jackson
  • , Noah Lechtzin
  • , Timothy M. Miller
  • , Bettina M. Cockroft
  • , Lisa Meng
  • , Jenny Wei
  • , Andrew A. Wolff
  • , Fady I. Malik
  • , Cynthia Bodkin
  • , Benjamin R. Brooks
  • , James Caress
  • , Annie Dionne
  • , Dominic Fee
  • , Stephen A. Goutman
  • , Namita A. Goyal
  • , Orla Hardiman
  • , Ghazala Hayat
    • Terry Heiman-Patterson, Daragh Heitzman, Robert D. Henderson, Wendy Johnston, Chafic Karam, Matthew C. Kiernan, Stephen J. Kolb, Lawrence Korngut, Shafeeq Ladha, Genevieve Matte, Jesus S. Mora, Merrilee Needham, Bjorn Oskarsson, Gary L. Pattee, Erik P. Pioro, Michael Pulley, Dianna Quan, Kourosh Rezania, Kerri L. Schellenberg, David Schultz, Christen Shoesmith, Zachary Simmons, Jeffrey Statland, Shumaila Sultan, Andrea Swenson, Leonard H.Van Den Berg, Tuan Vu, Steve Vucic, Michael Weiss, Ashley Whyte-Rayson, James Wymer, Lorne Zinman, Stacy A. Rudnicki

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science